ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,440.00
2.13%
Dow Jones
38,675.68
1.18%
Brent Oil
82.765
-1.03%
Bitcoin
62,460.42
5.65%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Calidi Biotherapeutics Inc (CLDI)

  7. Calidi Biotherapeutics Inc (CLDI) News

CLDI

Calidi Biotherapeutics (CLDI)

Calidi Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CLDI
DateTimeSourceHeadlineSymbolCompany
05/01/20247:00AMBusiness WireCalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingAMEX:CLDICalidi Biotherapeutics Inc
04/23/20247:00AMBusiness WireJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24AMEX:CLDICalidi Biotherapeutics Inc
04/19/20244:05PMBusiness WireCalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public OfferingAMEX:CLDICalidi Biotherapeutics Inc
04/16/20248:31AMBusiness WireCalidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public OfferingAMEX:CLDICalidi Biotherapeutics Inc
04/09/20247:00AMBusiness WireCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024AMEX:CLDICalidi Biotherapeutics Inc
03/15/20244:05PMBusiness WireCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
03/11/20247:00AMBusiness WireCalidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian CancerAMEX:CLDICalidi Biotherapeutics Inc
02/12/20247:00AMBusiness WireCalidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming ConferenceAMEX:CLDICalidi Biotherapeutics Inc
01/08/20247:00AMBusiness WireCalidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory BoardAMEX:CLDICalidi Biotherapeutics Inc
12/13/20237:00AMBusiness WireCalidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy SummitAMEX:CLDICalidi Biotherapeutics Inc
12/12/20237:00AMBusiness WireCalidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of DirectorsAMEX:CLDICalidi Biotherapeutics Inc
11/20/20237:00AMBusiness WireCalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical MilestonesAMEX:CLDICalidi Biotherapeutics Inc
11/14/20234:05PMBusiness WireCalidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
11/03/20237:00AMBusiness WireCalidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)AMEX:CLDICalidi Biotherapeutics Inc
11/01/20237:00AMBusiness WireCalidi Biotherapeutics Announces Key Leadership Promotions and New Board AppointmentAMEX:CLDICalidi Biotherapeutics Inc
10/30/20237:00AMBusiness WireCalidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial OfficerAMEX:CLDICalidi Biotherapeutics Inc
10/10/20237:00AMBusiness WireCalidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023AMEX:CLDICalidi Biotherapeutics Inc
09/13/20235:50AMBusiness WireCalidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted ImmunotherapiesAMEX:CLDICalidi Biotherapeutics Inc
 Showing the most relevant articles for your search:AMEX:CLDI

Your Recent History

USOTC
MWWC
Marketing Worldwide (PK)
USOTC
BLLB
Bell Buckle (PK)
USOTC
TKMO
Tekumo (PK)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
NASDAQ
JAGX
Jaguar Health
USOTC
YCRM
Yuenglings Ice Cream (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
MGON
Megola (PK)
USOTC
RDGL
Vivos (QB)
USOTC
GDVM
Global Developments (PK)
USOTC
MONI
Moon Equity (PK)
USOTC
UATG
Umbra Applied Technologies (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
ASRE
Astra Energy (QB)
USOTC
CLNV
Clean Vision (QB)
NASDAQ
TLRY
Tilray Brands
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved